Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
1(10%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_3
2
20%
Ph phase_4
4
40%
Ph phase_1
1
10%
Ph phase_2
3
30%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
4(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(7)

Detailed Status

Completed7
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)
Phase 44 (40.0%)

Trials by Status

not_yet_recruiting220%
recruiting110%
completed770%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT07576335Phase 2

Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy

Not Yet Recruiting
NCT07574268Phase 4

Efficacy of Transcutaneous Electrical Neural Stimulation and Tadalafil in Men With Erectile Dysfunction: A Randomized, Double-Blind, Bi-centric, Placebo- and Sham-Controlled Trial

Completed
NCT07563647Phase 4

Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome

Completed
NCT07416968Phase 4

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

Recruiting
NCT07333976Phase 2

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Completed
NCT07177326Phase 3

Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study

Not Yet Recruiting
NCT06947265Phase 4

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

Completed
NCT03240939Phase 1

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Completed
NCT00970632Phase 3

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

Completed
NCT00783094Phase 2

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10